Abstract: The present disclosure relates to amyloid beta (A?) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block AO channel activity and/or reduce A?-induced toxicity in a cell. Compositions comprised of compounds having histidine coordinating capacity are used in methods to prevent, reduce, or eliminate damage caused by A? ion channels.
Type:
Application
Filed:
March 18, 2009
Publication date:
January 20, 2011
Applicant:
he Henry M. JAckson Foundation for the Advancement of Military Medicine, Inc.